SLC6A3 and cancer: Cancer cases with DAT/SLC6A3 alteration(s) were significantly correlated with a poorer prognosis of cancer patients as compared to the no alteration group, as shown by the overall survival Kaplan-Meier estimate (Figure 7B, Table 1, Figure S9).